FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation

Full Text:


Objective – to conduct a pharmacoeconomic analysis of using omalizumab, mepolizumab and reslizumab in the treatment of patients with uncontrolled moderate and severe atopic asthma in the healthcare setting of the Russian Federation.

Materials and Methods. A pharmacoeconomic model based on clinical data was created. The cost-effectiveness ratios for omalizumab, mepolizumab and reslizumab were calculated and compared. Budget impact analysis for the partial replacement of omalizumab with mepolizumab and/or reslizumab has been performed.

Results. The use of omalizumab costs 13.3% less than that of reslizumab and 1.6% more than that of mepolizumab. The cost-effectiveness ratio for omalizumab is significantly lower vs the competitors. To prevent asthma exacerbations by omalizumab requires 463 805 rubles, which is 24.80% less than for reslizumab and by 382,640 or 20.89% less than for mepolizumab. The results are robust and resistant to 10% fluctuations in prices for the compared products. According to the budget impact analysis, by introducing reslizumab instead of omalizumab for a 3-year therapy in 210 patients with asthma and blood eosinophilia ≥400 cells/µl, will increase the burden on the budget by 13.25% or by 83.2 million rubles. In a group of 594 patients with eosinophilia ≥150 cells/µl, using mepolizumab instead of omalizumab will increase the budget burden by 1.58% or by 24.0 million rubles. In the total group of 759 patients receiving genetically-engineered products, switching to mepolizumab and reslizumab will increase the budget spending by 3.3% or 67.2 million rubles for 3 years.

Conclusion. The analysis shows that using omalizumab in patients with severe asthma that is uncontrolled by medium and high doses of inhaled corticosteroids, has the lowest burden on the budget of the healthcare system and is more effective compared to mepolizumab and reslizumab.

About the Authors

S. K. Zyryanov
Peoples’ Friendship University of Russia; City Clinical Hospital No. 24 of the Moscow Department of Health
Russian Federation

Sergey K. Zyryanov – MD, PhD, Professor & Head, Department of General and Clinical Pharmacology, Peoples’ Friendship University of Russia; Deputy Chief Medical Officer, Clinical Hospital No. 24, Department of Healthcare of the City of Moscow

ResearcherID: D-8826-2012
SPIN-код: 2725-9981

10/3 Miklukho-Maklaya Str., Moscow 117198
10 Pistsovaya Str., Moscow 27015 

I. N. Diyakov
Research Institute of Vaccines and Serums named after I.I. Mechnikov; Scientific and Practical Center for the Study of the Problems of Rational Pharmacotherapy and Pharmacoeconomics
Russian Federation

Ilya N. Diyakov – PhD (Biology), Head of the Laboratory of Biosynthesis of Immunoglobulines, Mechnikov Federal Research Institute of Vaccines and Sera; General Manager, Independent Center for Rational Pharmacotherapy and Pharmacoeconomics

SPIN-код: 1854-0958

5А Malyy Kazennyy pereulok, Moscow 105064
50, bld. 2 Aviamotornaya Str., Moscow 111024 

S. N. Avdeev
Sechenov University; Research Institute of Pulmonology, Federal Medical and Biological Agency
Russian Federation

Sergey N. Avdeev – MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Pulmonology, Sechenov First Moscow Medical University, Ministry of Health of the Russian Federation; Deputy Director for Science, Federal Institute for Pulmonology Research; Chief Pulmonologist, Ministry of Health of the Russian Federation

8-2 Trubetskaya Str., Moscow 119048
28 Orekhovyy bulvar, Moscow 115682 


1. Galimova E.S. The prevalence of bronchial asthma in the Republic of Bashkortostan and the clinical and immunological features of its combinations with digestive system diseases Avtoref. MD diss. 2013; Chelyabinsk. (in Russ.).

2. Reddel H.K., Taylor D.R., Bateman E.D. et al. An Official American Thoracic Society / European Respiratory Society Statement: Asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 2009; 180: 59-99.

3. Ilyina N.I. The burden of bronchial asthma. Problems of Russia. Effektivnaya farmakoterapiya. Allergologiya i immunologiya. 2014; 33 (2): 28-29. (in Russ.)

4. Severe bronchial asthma. Conciliation report of the joint expert group. Association of Russian-speaking specialists in the field of respiratory medicine. Russian Respiratory Society. Russian Association of Allergologists and Clinical Immunologists. 2018. (in Russ.)

5. Global Initiative for asthma (GINA). Global strategy for asthma management and prevention. Bethesda (MD): GINA, 2010.

6. Knyazheskaya N. P. Severe bronchial asthma. Lechebnoe delo (in Russ.). 2008; 2: 52-58.

7. Instructions for medical use of the drug mepolizumab. [Electronic resource] URL: Accessed: 30.04.19 (in Russ.).

8. Instructions for medical use of the drug islizumab. [Electronic resource] URL: Accessed: 30.04.19 (in Russ.).

9. Humbert M., Taillé C., Mala L., Le Gros V., Just J., Molimard M.; STELLAIR investigators. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018 May 10; 51 (5): pii: 1702523.

10. Ortega H.G., Liu M.C., Pavord I.D., Brusselle G.G., FitzGerald J.M., Chetta A., Humbert M., Katz L.E., Keene O.N., Yancey S.W., Chanez P. MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 Sep 25; 371 (13): 1198-207. Epub 2014 Sep 8.

11. Castro M., Zangrilli J., Wechsler M.E., Bateman E.D., Brusselle G.G., Bardin P., Murphy K., Maspero J.F., O’Brien C., Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015 May; 3 (5): 355-66. Epub 2015 Feb 23.

12. Instructions for medical use of omalizumab. [Electronic resource] URL: Accessed: 30.04.19 (in Russ.).

13. Belevskii A.S., Ilyina N.I., Knyazheskaya N.P., Kurbacheva O.M., Vishneva E.A., Namazova-Baranova L.S. Evaluation of the effectiveness of immunobiological therapy according to the analysis of current clinical practice in the management of patients with severe bronchial asthma. Data from the pilot project “All-Russian Register of Patients with Severe Asthma”. Prakticheskaya pul’monologiya. 2018; 4: 44-45. (in Russ.)

14. The protocol of the meeting of the commission of the Ministry of Health of the Russian Federation on the formation of lists of drugs for medical use and the minimum assortment of drugs needed to provide medical care from 04/19/2019. Moscow. 2019. [Electronic resource] URL: Accessed: 30.04.19 (in Russ.).

15. Kulikov A.Yu., Makarova E.I., Avdeev S.N. et al. Pharmacoeconomic analysis of the use of the drug resizumab in the treatment of severe bronchial asthma with an eosinophilic type of airway inflammation. Pul’monologiya. 2018; 28 (1): 50-60. (in Russ.)

16. The official website of the State Register of maximum selling prices. [Electronic resource] URL: PriceLims.aspx. Accessed: 30.04.19 (in Russ.).

17. Guidelines for conducting a comparative clinical and economic evaluation of a drug. FSBI Center for Expertise and Quality Control of Medical Care. Moscow. 2016; 20 s. (in Russ.)

18. Tran T.N., Zeiger R.S., Peters S.P., Colice G., Newbold P., Goldman M., Chipps B.E. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016 Jan; 116 (1): 37-42.

19. Guidelines for assessing the impact on the budget in the framework of the program of state guarantees of free medical care for citizens. Moscow. FSBI Center for Expertise and Quality Control of Medical Care. 2016; 27 s.


For citations:

Zyryanov S.K., Diyakov I.N., Avdeev S.N. Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019;12(4):268-278. (In Russ.)

Views: 1028

ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)